Atropine
Brand Names: Atropen Auto-Injector, Isopto Atropine
Methodology & AI Transparency ⓘ
Atropine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage atropen: is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients.
- 2 Real-world patient consensus: Tracked across 6 patient dosage logs with a 93% satisfaction benchmark (RxCUI 1190536).
- 3 Typical cash cost range: Dispensing cost comparison spans $33.75 mail/discount cash up to $82.69 uninsured retail (federal NADAC $5.0730).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Atropine): nausea (7.4%), headache (7.6%), dizziness (6.4%).
Ask our AI Specialists anything about Atropine
Atropine Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage atropen: is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. ATROPEN is a cholinergic muscarinic antagonist indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. ( 1 )
12.1 Mechanism of Action Atropine competitively blocks the effects of acetylcholine, including excess acetylcholine due to organophosphorus poisoning, at muscarinic cholinergic receptors on smooth muscle, cardiac muscle, secretory gland cells, and in peripheral autonomic ganglia and the central nervous system.
Clinical clearance of Atropine (Anticholinergic) relies on mixed metabolic conjugation and unchanged urinary excretion across atropine regimens with a Terminal t½ estimated at 4–9 hrs depending on renal/hepatic reserve (Atropine) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Atropine (2 mg/.7mL Injection) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after atropine administration.
FDA clinical labeling for Atropine restricts administration in severe drug-induced hypersensitivity to atropine or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2022-09-15 for atropine across 2 mg/.7mL Injection, .5 mg/.7mL Injection, 1 mg/.7mL Injection, .25 mg/.3mL Injection, 1% Solution Dropper, with self-reported patient tracking dominated by headache (7.6% of reports), nausea (7.4% of reports), dizziness (6.4% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Atropine (anticholinergic).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Atropine dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Atropine or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2022-09-15 for Atropine
Logged Side-Effect Incidence (6 Reports)
Atropine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Atropine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Negligible Rebound in Myopia Progression Following Cessation of Treatment with Atropine sulphate ophthalmic solution (0.01%) exhibited negligible rebound in myopia progression after treatment cessation following 3 years of. Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41949794 ↗ |
Atropine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $5.0730/unit (~$152.19/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $33.75 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $82.69 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $38.81 / mo | View logs ↓ |
Atropine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Atropine RxNorm Concept ID | 1190536 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $5.0730 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $82.69 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $33.75 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 93.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Atropine Patient Community, Cohort Filters & Dosage Logs
Deterministic Atropine reference combining NIH RxNorm (1190536), Medicaid NADAC ($5.0730/unit), and anonymous cohort outcomes (93% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Atropine community threads and patient logs by age, biological sex, dosage, and treatment duration.